Early diagnosis of cardiotoxic complications of chemotherapy: the possibility of radiation research methods
https://doi.org/10.18087/cardio.2512
Abstract
Oncological diseases are the main causes of death in the world. Modern treatment of cancer patients contributes to an increase in survival rate due to strong chemotherapeutic drugs, the use of which is accompanied by toxic effects on cardiomyocytes. The main manifestations of cardiotoxicity are left ventricular dysfunction, myocardial ischemia, thromboembolic complications, chronic heart failure. As a result, the risk of cardiovascular mortality may be higher than the risk of death from the tumor process. An important task of oncologists and cardiologists is the early diagnosis of cardiotoxic complications in order to start treatment in time and reduce mortality from cardiovascular pathology in cancer patients.
About the Authors
M. V. Chistyakova
Chita State Medical Academy
Russian Federation
Russian Federation
Gorkogo 39a, Chita 672090, Transbaikalia Region
E. V. Goncharova
Chita State Medical Academy
Russian Federation
Russian Federation
Gorkogo 39a, Chita 672090, Transbaikalia Region
References
1. Merabishvili V. M. Epidemiology and survival of breast cancer patients. Voprosy oncologii. 2013;59(3):314-9.
2. Vasyuk Yu. A., Shkolnik E. L., Nesvetov V. V., Shkolnik L. D., Selezneva M. G. Cardio-oncology: Current aspects in diagnostics for cardiovascular complications of antitumor therapy. Russian Heart Failure Journal. 2016;17(6):383-7. DOI: 10.18087/rh-fj.2016.6.2327
3. American Cancer Society. Breast Cancer Facts and Figures 2007— 2008. Atlanta: American Cancer Society, Inc.:1-36. Av. at: https:// www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2007-2008.pdf
4. O’Shaughnessy J, Twelves C, Aapro M. Treatment for anthracycline-pretreated metastatic breast cancer. The Oncologist. 2002;7 Suppl 6:4-12. PMID: 12454314
5. Higgins AY, O’Halloran TD, Chang JD. Chemotherapy-induced cardiomyopathy. Heart Failure Reviews. 2015;20(6):721-30. DOI: 10.1007/s10741-015-9502-y
6. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early Breast Cancer Therapy and Cardiovascular Injury.Journal of the American College of Cardiology. 2007;50(15):1435-41. DOI: 10.1016/j.jacc.2007.06.037
7. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonan-thracycline anticancer drugs. Expert Review of Anticancer Therapy. 2006;6(9):1249-69. DOI: 10.1586/14737140.6.9.1249
8. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of Cancer Therapy. Journal of Clinical Oncology. 2005;23(30):7685-96. DOI: 10.1200/JCO.2005.08.789
9. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet. 2007;370(9604):2011-9. DOI: 10.1016/S0140-6736(07)61865-0
10. Delemasure S, Vergely C, Zeller M, Cottin Y, Rochette L. Prevention de la cardiotoxicite des anthracyclines : approche fondamen-tale des mecanismes mis en jeu ; relations avec les donnees cliniques. Annales de Cardiologie et d’Angeiologie. 2006;55(2):104-12. DOI: 10.1016/j.ancard.2006.02.005
11. Vasyuk Yu. A., Shkolnik E. L., Nesterov V. V., Shkolnik L. D., Varlan G. V. Cardiooncology: Current Aspects of Prevention ofAnthracycline Toxicity. Kardiologiia. 2016;56(12):72-9.. DOI: 10.18565/cardio.2016.12.72-79
12. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 1997;11(12):931-6. PMID: 9337145
13. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthra-cycline derivates for reducing cardiotoxicity in cancer patients.
14. Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2010;21 Suppl 5:v277-282. DOI: 10.1093/annonc/mdq200
15. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzum-ab Therapy for Breast Cancer. Journal of the American College of Cardiology. 2012;60(24):2504-12. DOI: 10.1016/j.jacc.2012.07.068
16. Jensen BV Skovsgaard T, Nielsen SL. Functional monitoring ofanthra-cycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2002;13(5):699-709. PMID: 12075737
17. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteg-giano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(36):2768-801. DOI: 10.1093/eurheartj/ehw211
18. Jouven X, Escolano S, Celermajer D, EmpanaJ-P, Bingham A, Hermine O et al. Heart Rate and Risk of Cancer Death in Healthy Men. PLoS ONE. 2011;6(8):e21310. DOI: 10.1371/journal.pone.0021310
19. Cardinale D. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy. Circulation. 20 04; 109 (22): 2749-54. DOI: 10.1161/01.CIR.0000130926.51766.CC
20. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA et al. Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab. Journal of the American College of Cardiology. 2014;63(8):809-16. DOI: 10.1016/j.jacc.2013.10.061
21. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology. 2011;12(9):841-51. DOI: 10.1016/S1470-2045(11)70201-7
22. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M et al. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. Journal of Clinical Oncology. 2002;20(5):1215-21. DOI: 10.1200/JCO.2002.20.5.1215
23. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology. 2005;23(31):7811-9. DOI: 10.1200/JCO.2005.02.4091
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellik-ka PA et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005;18(12):1440-63. DOI: 10.1016/j.echo.2005.10.005
25. The task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (ESC). 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. Russian Journal of Cardiology. 2017;22(3):105-39.
26. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. Journal of the American College of Cardiology. 2003;42(4):743-9. PMID: 12932613
27. Alekhin M. A. Ultrasound methods for assessment of myocardial deformation and their clinical significance. - M.: Vidar-M, 2012. -85p.. ISBN 978-5-88429-164-5
28. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circulation. Cardiovascular Imaging. 2012;5(5):596-603. DOI: 10.1161/CIRCIMAGING.112.973321
29. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-Dimensional Echocardiography in Measuring Left Ventricular Volumes and Ejection Fraction. Journal of the American College of Cardiology. 2012;59(20):1799-808. DOI: 10.1016/j.jacc.2012.01.037
30. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume measurement with echocardiography: a comparison ofleft ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. European Heart Journal. 2008;30(1):98-106. DOI: 10.1093/eurheartj/ehn484
31. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.Journal of the American College of Cardiology. 2013;61(1):77-84. DOI: 10.1016/j.jacc.2012.09.035
32. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T et al. Role of Three-Dimensional Echocardiography in Breast Cancer: Comparison with Two-Dimensional Echocardiography, MultipleGated Acquisition Scans, and Cardiac Magnetic Resonance Imaging. Journal of Clinical Oncology. 2010;28(21):3429-36. DOI: 10.1200/JCO.2009.26.7294
33. Vasu S, Hundley W. Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance.Journal of Cardiovascular Magnetic Resonance. 2013;15(1):66. DOI: 10.1186/1532-429X-15-66
34. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Critical Reviews in Oncology/He-matology. 2003;45(1):55-75. PMID: 12482572
35. Thompson RC, Canby RC, Lojeski EW, Ratner AV Fallon JT, Po-host GM. Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties. American Heart Journal. 1987;113(6):1444-9. PMID: 3591613
36. Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study. American Heart Journal. 2001;141(6):1007-13. DOI: 10.1067/mhj.2001.115436
37. Grothues F, Smith GC, Moon JCC, Bellenger NG, Collins P, Klein HU et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. The American Journal of Cardiology. 2002;90(1):29-34. PMID: 12088775
38. Stoodley PW, Richards DAB, Hui R, Boyd A, Harnett PR, Meikle SR et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthra-cycline chemotherapy. European Journal of Echocardiography. 2011;12(12):945-52. DOI: 10.1093/ejechocard/jer187
39. Chaosuwannakit N, D’Agostino R, Hamilton CA, Lane KS, Ntim WO, Lawrence J et al. Aortic Stiffness Increases Upon Receipt of Anthracy-cline Chemotherapy. Journal of Clinical Oncology. 2010;28(1):166-72. DOI: 10.1200/JCO.2009.23.8527
40. Eckman DM, Stacey RB, Rowe R, DAgostino R, Kock ND, Sane DC et al. Weekly Doxorubicin Increases Coronary Arteriolar Wall and Adventitial Thickness. PLoS ONE. 2013;8(2):e57554. DOI: 10.1371/journal.pone.0057554
41. Holmes MD. Physical Activity and Survival After Breast Cancer Diagnosis. JAMA. 2005;293(20):2479. DOI: 10.1001/jama.293.20.2479
42. Jacobi B, Bongartz G, Partovi S, Schulte A-C, Aschwanden M, Lums-den AB et al. Skeletal muscle BOLD MRI: From underlying physiological concepts to its usefulness in clinical conditions.Journal ofMagnetic Resonance Imaging. 2012;35(6):1253-65. DOI: 10.1002/jm-ri.23536
43. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG et al. AC CF/ACR/AHA/NASCI/S CMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology. 2010;55(23):2614-62. DOI: 10.1016/j.jacc.2009.11.011
44. Seliverstova D. V., Evsina O. V. Cardiotoxicity of chemotherapy. Russian Heart Journal. 2016;15(1):50-7.. DOI: 10.18087/rhj.2016.1.2115
45. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology. 1998;5(6):579-90. PMID: 9869480
46. Wakasugi S, Fischman AJ, Babich JW, Aretz HT, Callahan RJ, Naka-ki M et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 1993;34(8):1283-6. PMID: 8326385
47. Gabrielson KL, Mok GSP, Nimmagadda S, Bedja D, Pin S, Tsao A et al. Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Molecular Imaging. 2008;7(3):132-8. PMID: 19123983
48. Behr TM, Behe M, Wormann B. Trastuzumab and Breast Cancer. New England Journal of Medicine. 2001;345(13):995-6. DOI: 10.1056/NEJM200109273451312
49. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WTA, de Korte MA, Jonkman S et al. Indium-111-Labeled Trastuzumab Scintigraphy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 2006;24(15):2276-82. DOI: 10.1200/JCO.2005.03.8448
50. Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Mana-tunga A et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. The AmericanJournal of Medicine. 1987;82(6):1109-18. DOI: 10.1016/0002-9343(87)90212-9
51. Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction non-invasively. Journal of Nuclear Cardiology. 2013;20(3):443-64. DOI: 10.1007/s12350-013-9707-1
52. Cottin Y, Touzery C, Coudert B, Gilles A, Walker P, Massing JL et al. Impairment of diastolic function during short-term anthracycline chemotherapy. British HeartJournal. 1995;73(1):61-4. PMID: 7888264
53. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Ber-riolo-Riedinger A et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Research and Treatment. 2011;130(3):845-54. DOI: 10.1007/s10549-011-1714-9
54. Ovchinnikov A. G., Vitsenya M. V., Ageev F. T. Role of a cardiologist in management of patients receiving antracyclines. Early detection and prevention of antracaycline-induced cardiomyopathy. Russian Heart Failure Journal. 2015;16 (6):396-404.. DOI: 10.18087/rhfj.2015.6.2159
55. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozen-cweig M et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine. 1979;91(5):710-7. PMID: 496103
Review
For citations:
Chistyakova M.V., Goncharova E.V. Early diagnosis of cardiotoxic complications of chemotherapy: the possibility of radiation research methods. Kardiologiia. 2018;58(12S):11-17. (In Russ.) https://doi.org/10.18087/cardio.2512
Views:
1500
Email this article 
Post a Comment 
